RICHMOND, Va., July 2, 2012 /PRNewswire/ -- avVaa World
Health Care Products, Inc. ("avVaa" or "the Company") (Pink
Sheets: AVVH) Today, avVaa announced a distribution agreement with
Eyedot Services Inc. to supply NEUROSKIN branded products to
Canadian Retail Drugstores beginning in July. NEUROSKIN is a
natural, mineral-based treatment for many skin conditions such as
acne, psoriasis and itching.
"We are very excited about the opportunity to introduce
NEUROSKIN to Canadian Drugstores," stated Ian Grantham, CEO of Eyedot Services Inc.
"We will feature NEUROSKIN Rejuvenate plus 3 additional skin
products to Canadian Drugstores initially targeting 6 stores in
Western Canada; however we plan to
expand throughout all of our Canadian Drugstores."
NEUROSKIN Rejuvenate will be available on store shelves to
provide relief from common summer sunburns. This all natural
topical spray promotes healing by quickly alleviating the
discomfort, itching and pain associated with most abrasions, burns
and skin irritations. With application, it lubricates, cools and
soothes the skin. Additional NEUROSKIN products will also be
available for the treatment of psoriasis, acne and itching.
"We have entered uncharted territory for avVaa as this is the
first time NEUROSKIN has been on the shelves in a physical retail
store," said Jason Price, President
and COO. "This partnership represents another major step for
avVaa in increasing our brand awareness and will ultimately launch
the company into continued growth for our shareholders taking us
from limited internet-based sales to the retail space."
NEUROSKIN is the second major product launch this year and
represents avVaa's dedication to natural, effective products that
are effective to the consumer and profitable to current
investors. Unlike many competitors, NEUROSKIN does not
contain cortisone, antibiotics, steroids or other unnatural
ingredients or additives. The formula is non-greasy and odorless,
does not stain clothing, and is easy to use.
About avVaa World Health Care Products, Inc.
avVaa is a global biotechnology company that specializes in
effective, natural, therapeutic skin care products that improve
quality of life and wellbeing for consumers. avVaa's patented
European skin care formulas are scientifically registered and
NHP-compliant. The formulas were developed to relieve and
treat the symptoms of common skin ailments, including eczema,
psoriasis and acne. avVaa is poised to manufacture and market
its OTC Neuroskin® line of skin care products through mass food and
drug channels in the United States
and globally. The Company's secondary line of equine and pet
care related products are already being distributed throughout all
of Canada. For more
information, visit: www.avvaa.com.
Jason Price
President & Chief Operating Officer
avVaa World Health Care Products, Inc.
Phone: 1-866-864-6598; Fax: 1-866-789-9336
Safe Harbor: This news release contains statements which
may constitute "forward‐looking statements" within the meaning of
the Securities Act of 1933 and the Securities Exchange Act of 1934,
as amended by the Private Securities Litigation Reform Act of 1995.
Those statements include statements regarding the intent, belief or
current expectations of avVaa World Health Care Products, and
members of its management, as well as the assumptions on which such
statements are based. Prospective investors are cautioned that any
such forward‐looking statements are not guarantees of future
performance and involve risks and uncertainties, and that actual
results may differ materially from those contemplated by such
forward‐looking statements. Important factors currently known to
management that could cause actual results to differ materially
from those in forward‐statements include fluctuation of operating
results, the ability to compete successfully and the ability to
complete before‐mentioned transactions. The Company undertakes no
obligation to update or revise forward‐looking statements to
reflect changed assumptions, the occurrence of unanticipated events
or changes to future operating results. Potential risks and
uncertainties include, but are not limited to, the ability to
procure, properly price, retain, and successfully complete
projects, the availability of technical personnel, changes in
technology, and competition.
SOURCE avVaa World Health Care Products, Inc.